Analysed BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) News Sources
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
25-03-2026
yahoo.com
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
01-04-2026
yahoo.com
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16
07-04-2026
yahoo.com
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
14-04-2026
yahoo.com
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
28-04-2026
yahoo.com
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
08-05-2026
yahoo.com
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
12-05-2026
yahoo.com
What is the current price of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The current price of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is $1.65.
BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) since the previous trading day is $0.
BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The most recent average sentiment score for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The most recent sentiment for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is .
SEC-8K** Filing Available For BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.